$LPCN
Lipocine Inc. Stock $lpcn

$lpcn Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-Q Financial Statement

#000114420418025522 Filed on May 07, 2018

Income Statement

Concept	2018 Q1	2017 Q1	2016 Q4
Revenue	$428.0K	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.690M	$1.830M	$1.340M
YoY Change	-7.65%	-58.41%	-30.57%
% of Gross Profit
Research & Development	$1.378M	$3.084M	$1.330M
YoY Change	-55.33%	15.35%	-51.99%
% of Gross Profit
Depreciation & Amortization	$10.00K	$10.00K	$10.00K
YoY Change	0.0%	0.0%	0.0%
% of Gross Profit
Operating Expenses	$3.065M	$4.909M	$2.680M
YoY Change	-37.56%	-30.57%	-42.98%
Operating Profit	-$2.637M	-$4.909M	-$3.015M
YoY Change	-46.28%	-30.57%	-35.8%
Interest Expense	$192.5K	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$82.29K	$48.36K	$50.00K
YoY Change	-270.17%	-19.41%	-16.67%
Pretax Income	-$2.719M	-$4.861M	-$2.970M
YoY Change	-44.05%	-30.65%	-35.85%
Income Tax	$700.00	$700.00	$0.00
% Of Pretax Income
Net Earnings	-$2.720M	-$4.861M	-$2.966M
YoY Change	-44.05%	-30.65%	-35.98%
Net Earnings / Revenue	-635.46%
Basic Earnings Per Share	-$0.13	-$0.26	-$0.16
Diluted Earnings Per Share	-$0.13	-$0.26	-$0.16
COMMON SHARES
Basic Shares Outstanding	21.26M	18.59M shares	18.26M shares
Diluted Shares Outstanding	21.26M	18.71M shares

Balance Sheet

Concept	2018 Q1	2017 Q1	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.76M	$26.80M	$26.84M
YoY Change	3.58%	-29.86%	-39.52%
Cash & Equivalents	$8.561M	$6.937M	$5.561M
Short-Term Investments	$19.20M	$19.86M	$21.28M
Other Short-Term Assets	$250.0K	$260.0K	$330.0K
YoY Change	-3.85%	-3.7%	-5.71%
Inventory
Prepaid Expenses
Receivables	$50.00K	$40.00K	$40.00K
Other Receivables	$3.560M	$0.00	$0.00
Total Short-Term Assets	$31.62M	$27.10M	$27.21M
YoY Change	16.68%	-29.87%	-39.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$30.00K	$100.0K	$100.0K
YoY Change	-70.0%	-9.09%	32.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$0.00
YoY Change			-100.0%
Other Assets	$20.00K	$30.00K	$30.75K
YoY Change	-33.33%	50.0%	29.47%
Total Long-Term Assets	$60.00K	$120.0K	$131.2K
YoY Change	-50.0%	-7.69%	-73.74%
TOTAL ASSETS
Total Short-Term Assets	$31.62M	$27.10M	$27.21M
Total Long-Term Assets	$60.00K	$120.0K	$131.2K
Total Assets	$31.68M	$27.22M	$27.34M
YoY Change	16.39%	-29.79%	-39.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$390.0K	$850.0K	$250.0K
YoY Change	-54.12%	-21.3%	-50.7%
Accrued Expenses	$305.1K	$1.491M	$1.080M
YoY Change	-79.55%	-22.32%	-62.55%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.340M
YoY Change
Total Short-Term Liabilities	$6.280M	$2.340M	$1.330M
YoY Change	168.38%	-21.74%	-60.79%
LONG-TERM LIABILITIES
Long-Term Debt	$8.724M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$8.724M	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.280M	$2.340M	$1.330M
Total Long-Term Liabilities	$8.724M	$0.00	$0.00
Total Liabilities	$15.01M	$2.340M	$1.330M
YoY Change	541.45%	-21.74%	-60.79%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock			$1.846K
YoY Change			1.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares	5.710K shares	5.710K shares	5.710K shares
Shareholders Equity	$16.67M	$24.88M	$26.02M
YoY Change
Total Liabilities & Shareholders Equity	$31.68M	$27.22M	$27.34M
YoY Change	16.39%	-29.79%	-39.75%

Cashflow Statement

Concept	2018 Q1	2017 Q1	2016 Q4
OPERATING ACTIVITIES
Net Income	-$2.720M	-$4.861M	-$2.966M
YoY Change	-44.05%	-30.65%	-35.98%
Depreciation, Depletion And Amortization	$10.00K	$10.00K	$10.00K
YoY Change	0.0%	0.0%	0.0%
Cash From Operating Activities	-$3.746M	-$3.139M	-$2.550M
YoY Change	19.35%	-51.79%	-12.67%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$900.0K	$1.430M	$2.830M
YoY Change	-162.94%	130.65%	-380.2%
Cash From Investing Activities	-$903.2K	$1.428M	$2.830M
YoY Change	-163.26%	146.19%	-380.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$2.698M
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.00M	$3.087M	580.0K
YoY Change	223.98%	10188.83%
NET CHANGE
Cash From Operating Activities	-3.746M	-$3.139M	-2.550M
Cash From Investing Activities	-903.2K	$1.428M	2.830M
Cash From Financing Activities	10.00M	$3.087M	580.0K
Net Change In Cash	5.351M	$1.376M	860.0K
YoY Change	288.91%	-123.32%	-121.88%
FREE CASH FLOW
Cash From Operating Activities	-$3.746M	-$3.139M	-$2.550M
Capital Expenditures		$0.00	$0.00
Free Cash Flow		-$3.139M	-$2.550M
YoY Change		-52.07%	-12.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	408227	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-4861260	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	632290	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-67509	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	607595	USD
CY2017Q4	us-gaap	Assets Assets	25325114	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	30753	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	25219291	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	411194	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3138751	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1427897	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	388551	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3746211	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-903225	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10000000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1375795	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5560716	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6936511	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2698098	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-2997	USD
CY2017Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	23067	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-19651	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3210749	USD
CY2018Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	19201374	USD
CY2017Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	18257321	USD
CY2018Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	47249	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4616	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	305064	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	598070	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3086649	USD
CY2017Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	6972103	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	8400000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	427280	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-160248	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-209714	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1191992	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5350564	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	24182	USD
CY2018Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	13210225	USD
CY2018Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	12300000	USD
CY2018Q1	us-gaap	Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax	-15035	USD
CY2017Q1	us-gaap	Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax	2707	USD
CY2017Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7093	USD
CY2018Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5261	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2719971	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4861260	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2719971	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4861260	USD
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18711239	shares
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21264539	shares
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	19221067	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	19201374	USD
CY2018Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	12300000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	294030	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	240570	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	53460	USD
CY2017Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	95000	USD
CY2018Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	83000	USD
CY2017Q4	lpcn	Common Stockpreferred Stockdebt Securitieswarrants And Units To Be Soldamountmaximum CommonStockpreferredStockdebtSecuritieswarrantsAndUnitsToBeSoldamountmaximum	150000000	USD
CY2017Q4	lpcn	Common Stock Additional Amount Authorized CommonStockAdditionalAmountAuthorized	25000000	USD
CY2015Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	63.96
CY2018Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2018Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2400000	USD
CY2018Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M6D
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	131000	USD
CY2013Q3	lpcn	Maximum Proceeds From Affiliates Under License Agreement MaximumProceedsFromAffiliatesUnderLicenseAgreement	10000000	USD
CY2013Q3	lpcn	Service Fee ServiceFee	230	USD
CY2018Q1	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	428000	USD
CY2013Q3	lpcn	Percentage Of Fee To Be Received PercentageOfFeeToBeReceived	0.2	pure
CY2018Q1	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	3566649	USD
CY2017Q4	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	3319927	USD
CY2018Q1	lpcn	Description Of Terms Of Service Agreement DescriptionOfTermsOfServiceAgreement	Under the service agreement, the Company provided facilities and up to 10 percent of the services of certain employees to Spriaso for a period of 18 months which expired
CY2017Q1	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	0	USD
CY2018Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	4250000	USD
CY2017Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	4250000	USD
CY2018Q1	us-gaap	Debt Current DebtCurrent	1340514	USD
CY2017Q4	us-gaap	Debt Current DebtCurrent	0	USD
CY2018Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	8724452	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2018Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1111366	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1121080	USD
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21270249	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21270249	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21264539	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21264539	shares
CY2018Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	5710	shares
CY2017Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	5710	shares
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	632290	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	427280	USD
CY2018Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-37478	USD
CY2017Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2018Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	48863	USD
CY2017Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	6169	USD
CY2018Q1	us-gaap	Increase Decrease In Insurance Settlements Receivable IncreaseDecreaseInInsuranceSettlementsReceivable	246722	USD
CY2017Q1	us-gaap	Increase Decrease In Insurance Settlements Receivable IncreaseDecreaseInInsuranceSettlementsReceivable	0	USD
CY2018Q1	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits	7000	USD
CY2017Q1	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits	0	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	10000000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	USD
CY2018Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	19221067	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	19693	USD
CY2018Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	19201374	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	18261937	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4616	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	18257321	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	19221067	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	19201374	USD
CY2018Q1	us-gaap	Collaborative Arrangement Rights And Obligations CollaborativeArrangementRightsAndObligations	All obligations under the prior license agreement have been completed except that Lipocine will owe Abbott a perpetual 1% royalty on net sales.
CY2018Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	26994986	USD
CY2017Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	20429135	USD
CY2018Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2018Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	3144000	USD
CY2018Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	3330000	USD
CY2018Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	3526000	USD
CY2018Q1	lpcn	Longterm Debt Maturities Repayments Of Principal After Year Four LongtermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour	0	USD
CY2018Q1	us-gaap	Long Term Debt LongTermDebt	10000000	USD
CY2018Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	428031	USD
CY2017Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	0	USD
CY2018Q1	us-gaap	Revenues Revenues	428031	USD
CY2017Q1	us-gaap	Revenues Revenues	0	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1377527	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3083739	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1687490	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1825176	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	3065017	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	4908915	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2636986	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4908915	USD
CY2018Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	110181	USD
CY2017Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	48355	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	192466	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	0	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-82285	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	48355	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2719271	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4860560	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	700	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	700	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-15035	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2707	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2735006	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4858553	USD
CY2017Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	666853	shares
CY2017Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4.33
CY2017Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2900000	USD
CY2018Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	700	USD
CY2017Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	700	USD
CY2018Q1	lpcn	Accrued Final Payment Charge On Debt AccruedFinalPaymentChargeOnDebt	64966	USD
CY2017Q1	lpcn	Accrued Final Payment Charge On Debt AccruedFinalPaymentChargeOnDebt	0	USD
CY2018Q1	us-gaap	Accretion Expense AccretionExpense	64966	USD
CY2017Q1	us-gaap	Accretion Expense AccretionExpense	0	USD

Files In Submission

Name	View Source	Status
0001144204-18-025522-index-headers.html	Edgar Link	pending
0001144204-18-025522-index.html	Edgar Link	pending
0001144204-18-025522.txt	Edgar Link	pending
0001144204-18-025522-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lpcn-20180331.xml	Edgar Link	completed
lpcn-20180331.xsd	Edgar Link	pending
lpcn-20180331_cal.xml	Edgar Link	unprocessable
lpcn-20180331_def.xml	Edgar Link	unprocessable
lpcn-20180331_lab.xml	Edgar Link	unprocessable
lpcn-20180331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv491769_10q.htm	Edgar Link	pending
tv491769_ex31-1.htm	Edgar Link	pending
tv491769_ex31-2.htm	Edgar Link	pending
tv491769_ex32-1.htm	Edgar Link	pending
tv491769_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LPCN
Lipocine Inc. Stock $lpcn

2018 Q1 Form 10-Q Financial Statement

#000114420418025522 Filed on May 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LPCN Lipocine Inc. Stock $lpcn

2018 Q1 Form 10-Q Financial Statement

#000114420418025522 Filed on May 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LPCN
Lipocine Inc. Stock $lpcn